Ikarian Capital

Ikarian Capital is a biotech investment firm focusing on innovations in drug discovery and development. Their team is led by professionals with deep scientific and biotech-specific finance backgrounds. They select companies pursuing cutting-edge science and demonstrating sound business fundamentals, spanning the spectrum of early- to late-stage clinical trials, agnostic to indication, market cap, or geography.

They pride themselves on being selective and contrarian, backed up by their proprietary process that plays to their team’s core expertise. They are committed to building an enduring business with strong values and high ethical standards.

Their investment approach is characterized by a focus on both long and short positions in biotechnology and pharmaceuticals, leveraging their co-founder’s medical and financial background. They have made several investments, including in companies like BioAtla, Solid Biosciences, and Renovacor. Their most recent investment was in Forte Biosciences on November 20, 2024.